2023
Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study
Theprungsirikul P, Liu Y, Neparidze N. Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study. Blood 2023, 142: 7364. DOI: 10.1182/blood-2023-186985.Peer-Reviewed Original ResearchFront-line treatmentBone marrow plasma cellsCommunity practice settingsR-ISS stageECOG performance statusRetrospective observational studyPerformance statusTransplant eligibilityPractice settingsCytogenetic abnormalitiesBone lesionsInsurance typeObservational studyTreatment responseEastern Cooperative Oncology Group performance statusInternational Myeloma Working Group criteriaYale New Haven Health SystemInternational Staging System stageRefractory multiple myeloma patientsUnfavorable-risk cytogeneticsGood partial responseFront-line therapyCD38 monoclonal antibodyMultiple myeloma patientsBetter treatment response
2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic value